



ASX ANNOUNCEMENT

Quarterly Cashflow Report

Melbourne Australia; 24 April 2013 - Starpharma Holdings Ltd (ASX: SPL; OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2013.

The cash balance at 31 March was \$35.9 million following the receipt of a \$5.4 million R&D tax incentive refund. This represents a net increase of \$2.7 million on the previous quarter.

On 3 April, Starpharma announced positive results for its Phase 2 clinical trial for the prevention of recurrence of bacterial vaginosis (BV). The trial, involving 205 women, showed that 1% VivaGel[®] demonstrated reduced risk of recurrent BV and delayed time to first recurrence. VivaGel[®] was safe and well tolerated by trial participants over the 16 week treatment period and high levels of patient satisfaction were reported with VivaGel[®]. On the strength of these results, Starpharma is planning to advance VivaGel[®] to Phase 3 studies for the prevention of recurrence indication, following input from FDA and other regulatory authorities.

Following the release in November 2012 of the Phase 3 results for VivaGel[®] for BV treatment, the company continues to make good progress with exploring alternative claim strategies, such as symptomatic relief and additional markets. The recent Phase 2 symptomatic results have added to this data set. These will be the subject of further discussions with the relevant authorities in coming few months and based on that regulatory feedback the possibility of making submissions based on these strategies will be pursued.

In other reported activity during the quarter, Starpharma signed a collaboration program with Makhteshim Agan, one of the world's leading manufacturers and distributors of branded off-patent crop products. Starpharma is applying its Priostar[®] dendrimer technology to novel crop formulations across Makhteshim Agan's extensive product portfolio.

ABOUT STARPHARMA

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel[®] portfolio, drug delivery, and agrochemicals with the Company developing a number of products internally and others via commercial partnerships.

Starpharma's lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (Tokyo Stock Exchange) to market a value-added, VivaGel®-coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world's second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Drug Delivery partners include GSK, Lilly and AstraZeneca. In its internal program Starpharma has announced significant tumour-targeting results in its docetaxel (Taxotere®) program, with animal studies showing its dendrimer-enhanced version of docetaxel to have significantly superior anti-cancer effects across a range of important cancer types including breast, prostate, lung and ovarian tumour, when compared to Taxotere® (docetaxel).

In agrochemicals Starpharma has a series of partnerships with leading industry players including Nufarm (ASX:NUF) and Makhteshim Agan as well as internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

FOR FURTHER INFORMATION

Media:

Buchan Consulting

Rebecca Wilson

Mob: +61 417 382 391

rwilson@buchanwe.com.au

Danny Rose

Mob: +61 407 25 00 88

drose@buchanwe.com.au

Starpharma:

Dr Jackie Fairley, Chief Executive Officer

+61 3 8532 2704

Ben Rogers, Company Secretary

ben.rogers@starpharma.com

www.starpharma.com

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Name of entity

Starpharma Holdings Limited

ABN

20 078 532 180

Quarter ended ("current quarter")

31 March 2013

Consolidated statement of cash flows

Cash flows related to operating activities

	Current Quarter \$A'000	Year to Date \$A'000
1.1 Receipts from customers and grants (including R&D Tax Incentive)	5,488	5,810
1.2 Payments for		
(a) staff costs	(1,169)	(3,694)
(b) advertising and marketing	-	-
(c) research and development	(2,154)	(10,944)
(d) other working capital	-	-
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	578	1,335
1.5 Interest and other costs of finance paid	(2)	(7)
1.6 Income taxes paid	-	-
1.7 Other	-	-
Net operating cash flows	2,741	(7,500)

Cash flows related to investing activities

1.9 Payment for acquisition of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	(9)	(118)
(e) other non-current assets	-	-
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	-	-
(b) equity investments	-	-
(c) intellectual property	-	-
(d) physical non-current assets	-	-
(e) other non-current assets	-	-
1.11 Loans to other entities	-	-
1.12 Loans repaid by other entities	-	-
1.13 Other	-	-
Net investing cash flows	(9)	(118)
1.14 Total operating and investing cash flows	2,732	(7,618)

Cash flows related to financing activities

1.15 Proceeds from issues of shares (net)	-	822
1.16 Proceeds from sale of forfeited shares	-	-
1.17 Proceeds from borrowings	-	-
1.18 Repayment of borrowings	-	-
1.19 Dividends paid	-	-
1.20 Other - lease repayments	(8)	(42)
Net financing cash flows	(8)	780

Net increase (decrease) in cash held

	2,724	(6,838)
1.21 Cash at beginning of quarter/year to date	33,182	42,812
1.22 Exchange rate adjustments	5	(63)
1.23 Cash at end of quarter	35,911	35,911

Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(196)
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Item 1.24 consists of the following:

- (a) Remuneration paid to the Chief Executive Officer.
- (b) Director's fees paid to non-executive directors.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

Nil

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities - Finance facility for laboratory equipment	200	106
3.2	Credit standby arrangements - Credit card facility	160	20

Item 3.1 A \$200,000 master asset finance facility with National Australia Bank for laboratory equipment, guaranteed by term deposit.

Reconciliation of cash

		Current quarter \$A'000	Previous quarter \$A'000
Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.			
4.1	Cash on hand and at bank	1,388	1,571
4.2	Deposits at call	34,523	31,611
4.3	Bank overdraft	-	-
4.4	Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)		35,911	33,182

Acquisitions and disposals of business entities

- 5.1 Name of entity
- 5.2 Place of incorporation or registration
- 5.3 Consideration for acquisition or disposal
- 5.4 Total net assets
- 5.5 Nature of business

Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
-	-
-	-
-	-
-	-
-	-

Compliance statement

1.

This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Law (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2. This statement does give a true and fair view of the matters disclosed.



24 April 2013

B P Rogers
Company Secretary